LPL Financial LLC Reduces Holdings in SPDR S&P Biotech (XBI)

LPL Financial LLC cut its position in SPDR S&P Biotech (NYSEARCA:XBI) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 256,087 shares of the exchange traded fund’s stock after selling 21,252 shares during the quarter. LPL Financial LLC’s holdings in SPDR S&P Biotech were worth $21,734,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in SPDR S&P Biotech by 4.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,511,948 shares of the exchange traded fund’s stock valued at $128,318,000 after purchasing an additional 62,486 shares during the last quarter. Assetmark Inc. raised its position in shares of SPDR S&P Biotech by 59.9% during the third quarter. Assetmark Inc. now owns 1,239,051 shares of the exchange traded fund’s stock worth $107,265,000 after acquiring an additional 464,246 shares during the last quarter. Alliancebernstein L.P. bought a new position in shares of SPDR S&P Biotech during the fourth quarter worth about $75,489,000. First Republic Investment Management Inc. raised its position in shares of SPDR S&P Biotech by 7.0% during the fourth quarter. First Republic Investment Management Inc. now owns 437,264 shares of the exchange traded fund’s stock worth $37,110,000 after acquiring an additional 28,519 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of SPDR S&P Biotech by 27.6% during the fourth quarter. SG Americas Securities LLC now owns 387,352 shares of the exchange traded fund’s stock worth $32,875,000 after acquiring an additional 83,730 shares during the last quarter.

How to Become a New Pot Stock Millionaire

SPDR S&P Biotech (NYSEARCA:XBI) opened at $93.57 on Friday. SPDR S&P Biotech has a 1 year low of $66.00 and a 1 year high of $97.98. The stock has a market capitalization of $5,120.00 and a PE ratio of 5.13.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 21st. Stockholders of record on Monday, March 19th will be given a dividend of $0.0591 per share. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.25%. This is an increase from SPDR S&P Biotech’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Friday, March 16th. SPDR S&P Biotech’s dividend payout ratio (DPR) is 1.10%.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3275569/lpl-financial-llc-reduces-holdings-in-spdr-sp-biotech-xbi.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Liberum Capital Reiterates Hold Rating for Sports Direct
Liberum Capital Reiterates Hold Rating for Sports Direct
RWS  Rating Reiterated by Shore Capital
RWS Rating Reiterated by Shore Capital
WPP’s  Hold Rating Reiterated at Deutsche Bank
WPP’s Hold Rating Reiterated at Deutsche Bank
Berenberg Bank Raises Ten Entertainment Group  Price Target to GBX 310
Berenberg Bank Raises Ten Entertainment Group Price Target to GBX 310
Evonik Industries  Given a €27.00 Price Target by UBS Analysts
Evonik Industries Given a €27.00 Price Target by UBS Analysts
eMagin  Sees Large Decline in Short Interest
eMagin Sees Large Decline in Short Interest


© 2006-2018 Ticker Report. Google+.